Transgene Company Overview and Insights

Author

Reads 3.8K

Factory
Credit: pexels.com, Factory

Transgene is a biotech company that has been around since 1988, making it a seasoned player in the industry. It's headquartered in Strasbourg, France, and has a presence in the US.

The company specializes in developing immunotherapy treatments, focusing on cancer and infectious diseases. Its expertise lies in using viruses as vectors to deliver genetic material to cells.

Transgene has a diverse portfolio of products in various stages of development, from preclinical to Phase III clinical trials. This indicates a commitment to innovation and progress.

Its lead product, MAVIRET, is an HIV treatment that has shown promising results in clinical trials, demonstrating the company's ability to bring effective solutions to market.

Products and Technology

Transgene is a biotechnology company focused on designing and developing novel immunotherapies for the treatment of cancer. Their main focus is on creating cutting-edge immunotherapeutic products to treat cancers and chronic infectious diseases.

The company has two technological platforms: Invir.IO and myvac. Invir.IO is based on patented oncolytic viruses that replicate only in cancer cells, while myvac is based on an MVA vector that enables the design of personalized viruses based on each patient's tumor mutations.

Credit: youtube.com, Panel: Gene Therapy: Building the Gene Medicine Pipeline Through Next Generation Technologies

Transgene's products in development include TG4050, a neoantigen individualized therapeutic cancer vaccine, and TG4001, a therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus. Their oncolytic viruses, TG6050 and BT-001, are designed to directly and selectively destroy cancer cells.

The company has a strong pipeline of products, with four products currently in clinical development. These include TG4010, which is in phase 2/3 trial for the treatment of Non-Small Cell Lung Cancer, and TG4001, which has completed phase 2 trials in HPV-induced pre-cancerous lesions of the cervix.

Transgene's products utilize three types of vectors: Modified Vaccinia Ankara (MVA), vaccinia virus, and adenovirus. The company's expertise covers all stages of product development, from research to the manufacture of clinical batches, and the conducting of clinical trials.

Here are some of the products in Transgene's pipeline:

  • TG4050: neoantigen individualized therapeutic cancer vaccine
  • TG4001: therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus
  • TG6050: oncolytic virus designed to directly and selectively destroy cancer cells
  • BT-001: oncolytic virus designed to directly and selectively destroy cancer cells

Transgene's technology platforms, Invir.IO and myvac, aim to help patients fight life-threatening diseases through restoring the immune system's capacity to eliminate abnormal or infected cells.

Management and Partnerships

A Man Writing on the Contract
Credit: pexels.com, A Man Writing on the Contract

Transgene's Management Committee is made up of experienced professionals, led by Alessandro Riva as Chairman & CEO and Hedi Ben Brahim also serving as Chairman & CEO.

The committee includes other key members such as Éric Quéméneur, Executive Vice-President and Chief Scientific Officer, and Christophe Ancel, Vice-President of Pharmaceutical Operations.

Transgene has a strong network of partners, including Novartis, Jennerex, and the European cooperative group EORTC.

Employee Count and Recruitment Strategy

Our company has a highly skilled workforce of 270 full-time employees. They joined us from major pharmaceutical and biotechnology companies, as well as from research academic institutions.

What attracts top talent to our company is the maturity of our pipeline and our focus on finding solutions to today's major unmet medical needs.

Management Committee

Transgene's Management Committee is a group of highly experienced professionals who oversee the company's operations and strategy.

The committee is led by Alessandro Riva, who serves as both the Chairman and Chief Executive Officer (CEO).

Credit: youtube.com, Fundamentals of Labor-Management Committees

Hedi Ben Brahim also holds the position of Chairman and CEO, suggesting a shared leadership approach.

Éric Quéméneur is the Executive Vice-President and Chief Scientific Officer (CSO), responsible for driving the company's scientific direction.

Christophe Ancel serves as the Vice-President of Pharmaceutical Operations and is a qualified pharmacist.

Maud Brandely-Talbot is the Vice-President of Medical Affairs and Chief Medical Officer (CMO), overseeing the company's medical strategy.

Jean-Philippe Del is the Vice-President and Chief Financial Officer (CFO), handling the company's financial matters.

Thibaut du Fayet is the Vice-President of Corporate Development, focusing on partnerships and growth initiatives.

John Felitti is the Vice-President, General Counsel, and Corporate Secretary, responsible for the company's legal and governance aspects.

Gaëlle Stadtler is the Vice-President and Human Resources Director, managing the company's human resources functions.

Here is a list of the Management Committee members:

  • Alessandro Riva, Chairman & CEO
  • Hedi Ben Brahim, Chairman & CEO
  • Éric Quéméneur, Executive Vice-President & CSO
  • Christophe Ancel, Vice-President Pharmaceutical Operations & Qualified Pharmacist
  • Maud Brandely-Talbot, Vice-President Medical Affairs & CMO
  • Jean-Philippe Del, Vice-President & CFO
  • Thibaut du Fayet, Vice-President Corporate Development
  • John Felitti, Vice-President, General Counsel, Corporate Secretary
  • Gaëlle Stadtler, Vice-President, Human Resources Director

Key Partners

Our key partners are instrumental in helping us achieve our goals. Novartis, a renowned pharmaceutical company, is one of our most important partners.

Credit: youtube.com, Understanding Key Partners in the Business Model Canvas (3 Minutes)

We also collaborate with start-ups like Jennerex, a San Francisco-based company, to bring innovative ideas to the table. The leading European cooperative group EORTC is another valued partner.

Our approach to business development focuses on retaining as much value as possible while securing long-term financing. This means we aim to retain development and/or marketing or co-promotion rights whenever possible.

Attracting partners is a key aspect of our strategy. We achieve this through cutting-edge science, excellent development capabilities, strong Intellectual Property, and an entrepreneurial mindset.

Financials and Performance

Transgene's financial performance is a mixed bag. The company's trailing total returns as of October 20, 2025, are not impressive, considering the CAC 40 benchmark.

The profitability of Transgene is also a concern, with a profit margin of 0.00%. This suggests that the company is not generating enough revenue to cover its costs.

Here are some key financial metrics for Transgene:

  • Profit Margin: 0.00%
  • Return on Assets (ttm): -49.35%
  • Revenue (ttm): 7.58M
  • Net Income Available to Common (ttm): -36.78M
  • Diluted EPS (ttm): -0.2800

Transgene's net income is significantly negative, indicating that the company is losing money. This is likely due to high expenses or low revenue.

TNG PA Performance

Two scientists in protective gear conducting an experiment with green liquid in laboratory setting.
Credit: pexels.com, Two scientists in protective gear conducting an experiment with green liquid in laboratory setting.

TNG PA Performance is a bit of a mixed bag. The trailing total returns as of 10/20/2025 are not exactly impressive, but they do include dividends or other distributions.

The company's performance is heavily influenced by its profitability. Unfortunately, the profit margin is a whopping 0.00%. This suggests that TNG PA is not generating a lot of profit from its sales.

Let's take a look at the company's income statement. Here are some key metrics:

As you can see, TNG PA has some major red flags when it comes to profitability. The return on assets is a staggering -49.35%, which suggests that the company is not generating enough revenue to cover its expenses. The net income available to common shareholders is also a negative -36.78M, which is not a good sign.

Valuation Measures

In this section, we'll take a closer look at the valuation measures of the company.

The Enterprise Value of the company is 158.71M.

Credit: youtube.com, FINANCIAL RATIOS: How to Analyze Financial Statements

This is a significant indicator of the company's size and value. I've seen companies with a high Enterprise Value tend to have a strong market presence.

The Price/Book (mrq) ratio is 8.86, which is a key metric for investors to consider.

A high Price/Book ratio can indicate that investors are willing to pay a premium for the company's assets.

The Price/Sales (ttm) ratio is 403.40, which is a significant multiple.

This suggests that investors are valuing the company's sales at a high multiple, which can be a sign of strong growth potential.

Here's a summary of the key valuation metrics:

  • Enterprise Value: 158.71M
  • Price/Book (mrq): 8.86
  • Price/Sales (ttm): 403.40

Who Is Your Competition and What Makes Your Product Better?

Transgene is not alone in the market for viral-based products for therapy of cancer and infectious diseases. Our competitors include Transgene SA, Innate Pharma SA, Neovacs SA, and Quantum Genomics SA.

These companies are all based in France, with headquarters located in Illkirch-Graffenstaden, Marseille, Suresnes, and Paris respectively.

Expand your knowledge: Worldline SA

Credit: youtube.com, Strategies of Transgene Biotek Limited 2014

Transgene's products offer a unique combination of innate and adaptive immune responses against cancer and infectious diseases and antigens, giving us an edge over our competitors.

Here's a comparison of our key parameters with those of our competitors:

Our smaller team size compared to Innate Pharma and Transgene SA may actually be a benefit, allowing for more focused and agile development.

Regulatory and Clinical

Transgene's clinical operations are a crucial aspect of their business. They have a clinical-stage product in development, TG4050, which is a neoantigen individualized therapeutic cancer vaccine being developed in a randomized Phase I/II trial for the adjuvant treatment of head and neck cancer.

The company is also evaluating the full study results for another product, TG4001, a therapeutic vaccine designed to express the E6 and E7 antigens of the HPV-16 virus. This product is currently in the development stage.

Transgene is collaborating with AstraZeneca to co-develop oncolytic viruses from the Invir.IO platform. These oncolytic viruses, including TG6050 and BT-001, are designed to directly and selectively destroy cancer cells while inducing immune responses against tumor cells.

Clinical Trials

Credit: youtube.com, What is Regulatory Affairs Management in Clinical Research?

Clinical trials are a crucial step in bringing new treatments to market, and Transgene SA is no exception. Their clinical trials are focused on determining the go-to-market proposition and gaining insight into the company's clinical operations, recruitment, and trial strategy.

Transgene SA has several products in development, including therapeutic vaccines and oncolytic viruses. One of their flagship products, myvac, is a platform that creates individualized immunotherapies to destroy cancer tumors.

The myvac platform uses AI to select targets most likely to induce a strong immune response and incorporates these neoantigens into a viral vector. This approach is tailor-made for each patient, based on the mutations specific to their tumor.

Transgene SA is currently conducting a randomized Phase I/II trial for TG4050, a neoantigen individualized therapeutic cancer vaccine, in the adjuvant treatment of head and neck cancer.

Here are some of the key products in development by Transgene SA:

These products are at various stages of development, with TG4050 currently in a Phase I/II trial and TG4001 undergoing evaluation of full study results.

Regulatory Milestones

Credit: youtube.com, FDA Regulatory Milestones

Regulatory milestones are crucial for pharma companies to stay ahead.

Track drug and patent expiries, which can significantly impact a company's revenue and market share.

Knowing the geographies impacted by these expiries can help companies focus their resources on the most critical areas.

Industry Analytics

Transgene's access to investigative journalist content can help remove risk and uncertainty, giving the company a competitive edge.

This is because investigative journalist content can provide actionable leads, allowing Transgene to make informed decisions.

Securing actionable leads can be a game-changer for any company, and Transgene is no exception.

By gaining a competitive edge, Transgene can stay ahead of the curve and achieve its goals.

Access to company-related investigative journalist content can be a valuable resource for Transgene, helping to drive success.

Maurice Pollich

Senior Writer

Maurice Pollich is a seasoned writer with a keen interest in the digital world. With a background in technology and finance, he brings a unique perspective to his writing. Maurice's expertise spans a range of topics, including cryptocurrency tokens, where he has developed a deep understanding of the underlying mechanics and market trends.

Love What You Read? Stay Updated!

Join our community for insights, tips, and more.